Insider · CIK 0001393547

Benjamin Howard

Reports to the SEC for 1 company · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001393547

Forms 4 and 5

Insider transactions

49 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2017-12-14	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−6,021 sh	—	—	3,010
2017-12-14	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−4,062 sh	—	—	8,124
2017-12-14	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+2,646 sh	$15.91	+$42.1K	36,554
2017-12-14	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+6,021 sh	$26.20	+$158K	42,575
2017-12-14	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+4,062 sh	$26.05	+$106K	46,637
2017-12-14	RGENREPLIGEN CORPS Sale	VP Business Development	SSale	−12.7K sh	$35.34	−$450K	33,908
2017-12-14	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−2,646 sh	—	—	0
2017-03-20	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−10K sh	—	—	0
2017-03-20	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+4,968 sh	$15.91	+$79K	36,124
2017-03-20	RGENREPLIGEN CORPS Sale	VP Business Development	SSale	−4,968 sh	$34.61	−$172K	31,156
2017-03-20	RGENREPLIGEN CORPS Sale	VP Business Development	SSale	−7,248 sh	$34.63	−$251K	23,908
2017-03-20	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+10K sh	$6.23	+$62.3K	33,908
2017-03-20	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−4,968 sh	—	—	0
2017-03-01	RGENREPLIGEN CORPF Tax Payment	VP Business Development	FTax Payment	−1,976 sh	$32.08	−$63.4K	31,156
2017-02-23	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	VP Business Development	AAward	+8,289 sh	—	—	8,289
2017-02-23	RGENREPLIGEN CORPA Award	VP Business Development	AAward	+4,506 sh	—	—	33,132
2017-02-23	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	VP Business Development	AAward	+9,012 sh	—	—	9,012
2017-02-23	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	VP Business Development	AAward	+9,012 sh	—	—	9,012
2016-05-24	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−10K sh	—	—	10,000
2016-05-24	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+10K sh	$6.23	+$62.3K	28,626
2016-05-11	RGENREPLIGEN CORPS Sale	VP Business Development	SSale	−2,889 sh	$26.72	−$77.2K	18,626
2016-02-29	RGENREPLIGEN CORPF Tax Payment	VP Business Development	FTax Payment	−1,302 sh	$26.05	−$33.9K	21,515
2016-02-26	RGENREPLIGEN CORPA Award	VP Business Development	AAward	+6,263 sh	—	—	22,817
2016-02-26	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	VP Business Development	AAward	+12.2K sh	—	—	12,186
2015-11-19	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−5,000 sh	—	—	0
2015-11-19	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+5,000 sh	$3.33	+$16.7K	16,554
2015-06-09	RGENREPLIGEN CORPS Sale	VP Business Development	SSale	−7,697 sh	$37.48	−$288K	11,554
2015-06-08	RGENREPLIGEN CORPS Sale	VP Business Development	SSale	−27.3K sh	$38.32	−$1.05M	19,251
2015-03-18	RGENREPLIGEN CORPS Sale	VP Business Development	SSale	−15.8K sh	$32.63	−$515K	46,554
2015-03-18	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+10K sh	$6.23	+$62.3K	58,542
2015-03-18	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+3,807 sh	$15.91	+$60.6K	62,349
2015-03-18	RGENREPLIGEN CORP · StockOption (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−10K sh	—	—	20,000
2015-03-18	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−3,807 sh	—	—	7,614
2015-02-26	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	VP Business Development	AAward	+9,031 sh	—	—	9,031
2015-02-26	RGENREPLIGEN CORPA Award	VP Business Development	AAward	+4,691 sh	—	—	48,542
2014-11-11	RGENREPLIGEN CORPS Sale	VP Business Development	SSale	−30K sh	$23.56	−$707K	43,851
2014-08-13	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+5,000 sh	$3.33	+$16.7K	113,851
2014-08-13	RGENREPLIGEN CORPS Sale	VP Business Development	SSale	−40K sh	$20.34	−$814K	73,851
2014-08-13	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−5,000 sh	—	—	5,000
2014-02-27	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	VP Business Development	AAward	+11.4K sh	—	—	11,421
2014-02-27	RGENREPLIGEN CORPA Award	VP Business Development	AAward	+5,962 sh	—	—	28,926
2013-05-06	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+13K sh	$4.25	+$55.1K	22,964
2013-05-06	RGENREPLIGEN CORPM Exercise/Conversion	VP Business Development	MExercise/Conversion	+10K sh	$3.33	+$33.3K	26,731
2013-05-06	RGENREPLIGEN CORPF Tax Payment	VP Business Development	FTax Payment	−3,767 sh	$8.84	−$33.3K	22,964
2013-05-06	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−13K sh	—	—	152,036
2013-05-06	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	VP Business Development	MExercise/Conversion	−10K sh	—	—	142,036
2013-05-06	RGENREPLIGEN CORPF Tax Payment	VP Business Development	FTax Payment	−6,233 sh	$8.84	−$55.1K	16,731
2013-02-28	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	VP Business Development	AAward	+40K sh	—	—	165,000
2009-01-05	RGENREPLIGEN CORPA Award	VP Business Development	AAward	+10K sh	$0.01	+$100	10,000

Recent filings

Accepted (ET)
Dec 184
Benjamin Howard0001140361-17-046579
SEC(opens sec.gov)
May 224/A
REPLIGEN CORP0001140361-17-021773
SEC(opens sec.gov)
Mar 224
REPLIGEN CORP0001140361-17-012940
SEC(opens sec.gov)
Mar 214/A
REPLIGEN CORP0001140361-17-012884
SEC(opens sec.gov)
Mar 14
REPLIGEN CORP0001140361-17-010119
SEC(opens sec.gov)
May 264
REPLIGEN CORP0001140361-16-067304
SEC(opens sec.gov)

Companies

REPLIGEN CORPVP Business DevelopmentRGEN

Address

C/O REPLIGEN CORPORATION 41 SEYON STREET

WALTHAM, MA, 02453